Nanobiotix Launches Curadigm Facility with Nanoprimer Technology in France and the US

Shots:

• Nanobiotix launches a new subsidiary, Curadigm along with its Nanoprimer technology to reshape the balance b/w bioavailability, toxicity, and efficacy in the healthcare system in France & the US
• Nanobiotix will remain focus on its lead candidate NBTXR3 to expand radiotherapy benefits and its Immuno-Oncology program to innovate cancer immunotherapies and has also received marketing approval in Europe
• Curadigm technology increases the efficacy at current doses, decreases toxicity & cost, allowing to utilize new approaches for drug designing and is presented at AACR 2019

Click here to read full press release/ article | Ref: GlobeNewsWire | Image: My French Startup